Related Experiment Video
Updated: Jun 28, 2026

Utilizing Murine Inducible Telomerase Alleles in the Studies of Tissue Degeneration/Regeneration and Cancer
Published on: April 13, 2015
MSH2 deficiency abolishes the anticancer and pro-aging activity of short telomeres
Paula Martinez1, Irene Siegl-Cachedenier, Juana M Flores
1Spanish National Cancer Centre, Madrid, Spain.
Abstract:
Mutations in the mismatch repair (MMR) pathway occur in human colorectal cancers with microsatellite instability. Mounting evidence suggests that cell-cycle arrest in response to a number of cellular stresses, including telomere shortening, is a potent anticancer barrier. The telomerase-deficient mouse model illustrates the anticancer effect of cell-cycle arrest provoked by short telomeres. Here, we describe a role for the MMR protein, MSH2, in signaling cell-cycle arrest in a p21/p53-dependent manner in response to short telomeres in the context of telomerasedeficient mice. In particular, progressively shorter telomeres at successive generations of MSH2(-/-) Terc(-/--) mice did not suppress cancer in these mice, indicating that MSH2 deficiency abolishes the tumor suppressor activity of short telomeres. Interestingly, MSH2 deficiency prevented degenerative pathologies in the gastrointestinal tract of MSH2(-/-) Terc(-/-) mice concomitant with a rescue of proliferative defects. The abolishment of the anticancer and pro-aging effects of short telomeres provoked by MSH2 abrogation was independent of changes in telomere length. These results highlight a role for MSH2 in the organismal response to dysfunctional telomeres, which in turn may be important in the pathobiology of human cancers bearing mutations in the MMR pathway.
Insights
Mismatch repair (MMR) protein MSH2 signals cell-cycle arrest due to short telomeres. MSH2 deficiency abolishes the tumor suppressor activity of short telomeres, impacting cancer and aging.
Area of Science:
- Genetics
- Cancer Biology
- Molecular Biology
Background:
- Mutations in the mismatch repair (MMR) pathway are common in human colorectal cancers.
- Cell-cycle arrest triggered by cellular stresses like telomere shortening acts as an anticancer mechanism.
- Telomerase-deficient mouse models demonstrate the anticancer role of short telomeres.
Purpose of the Study:
- To investigate the role of the MMR protein MSH2 in cell-cycle arrest in response to short telomeres.
- To determine if MSH2 deficiency affects the tumor suppressor activity of short telomeres.
- To explore the impact of MSH2 on degenerative pathologies and proliferative defects in telomerase-deficient mice.
Main Methods:
- Utilized MSH2(-/-) Terc(-/-) mice, a telomerase-deficient model.
- Observed telomere length across successive generations.
- Assessed cancer suppression, degenerative pathologies, and proliferative defects.
Main Results:
- MSH2 deficiency abolished the tumor suppressor activity of short telomeres, as cancer was not suppressed in MSH2(-/-) Terc(-/-) mice.
- MSH2 deficiency prevented gastrointestinal degenerative pathologies and rescued proliferative defects.
- These effects were independent of changes in telomere length.
Conclusions:
- MSH2 plays a critical role in the organismal response to dysfunctional telomeres.
- MSH2's function in telomere maintenance and cell-cycle arrest is crucial for tumor suppression and preventing aging-related pathologies.
- Understanding MSH2's role may offer insights into human cancers with MMR pathway mutations.
Related Concept Videos
Replicative Cell Senescence
Abnormal Proliferation
Mismatch Repair
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
Mismatch Repair
Telomeres and Telomerase
Telomeres and Telomerase

